Artificial Lymph Node Scaffold for Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dendritic cell-based vaccines for treating type 1 diabetes face challenges such as high cost, adverse patient safety, and suboptimal ex vivo stability, and there is a need for improved vaccine techniques and compositions that can modulate immune responses effectively for preventing and treating infections, cancer, and autoimmune diseases.
Innovation Solution
The development of an artificial lymph-node and spleen environment using a scaffold matrix made of biocompatible materials that encapsulates pro-inflammatory and anti-inflammatory agents, along with antigens or allergens, to modulate immune responses by creating a dual-environment for immune cell activation and tolerance induction, utilizing chemoattractants like GM-CSF and G-CSF to direct immune cells and provide timed release of adjuvants and therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dendritic cell-based vaccines are used for treating type 1 diabetes, then immune response modulation is achieved, but patient safety deteriorates and cost increases
Solution Approach 1:
The patent creates an artificial lymph-node environment that replicates the natural lymph node structure and function using scaffold materials. This artificial environment copies the essential features of real lymph nodes to achieve immune modulation without requiring extraction and modification of patient's own dendritic cells, thereby improving safety while maintaining efficacy
Solution Approach 2:
The scaffold matrix acts as an intermediary structure that provides a controlled environment for immune cell interaction. Instead of directly manipulating patient cells (which causes safety issues), the scaffold serves as a mediator that facilitates immune response modulation through its structure and embedded agents
2Reliability
If dendritic cell-based vaccines are used for treating type 1 diabetes, then immune response modulation is achieved, but manufacturing cost increases
Solution Approach 1:
By creating an artificial lymph-node environment using synthetic scaffold materials rather than requiring complex ex vivo cell culture and modification processes, the manufacturing becomes simpler and more cost-effective while maintaining the ability to modulate immune responses
Solution Approach 2:
The patent changes the approach from biological cell-based therapy to a material-based artificial environment, fundamentally altering the manufacturing parameters from complex cellular processing to scaffold fabrication and agent incorporation, thereby reducing cost
3Reliability
If dendritic cell-based vaccines are used, then immune response modulation is achieved, but ex vivo stability deteriorates
Solution Approach 1:
The artificial lymph-node environment replicates the stable structural framework of natural lymph nodes using robust scaffold materials, providing a stable platform that maintains immune modulation function without the instability associated with ex vivo cultured dendritic cells
Solution Approach 2:
The scaffold matrix uses porous materials that provide structural stability while allowing immune cell infiltration and interaction. This porous structure maintains the stability of the artificial environment while enabling the dynamic immune responses needed for therapy
4Reliability
If conventional vaccine design focuses on pro-inflammatory responses, then protective immunity against infections is improved, but autoimmune disease treatment deteriorates
Solution Approach 1:
The artificial lymph-node environment is designed to be multi-functional, capable of inducing both pro-inflammatory responses for infection protection and anti-inflammatory tolerance for autoimmune disease treatment. The same scaffold system can be programmed with different agents to achieve different therapeutic outcomes
Solution Approach 2:
The patent changes the inflammatory parameter programming of the immune response by controlling the composition and release kinetics of agents within the scaffold. By adjusting these parameters, the system can shift between pro-inflammatory and anti-inflammatory states to treat different disease conditions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively prevents and treats pathogenic infections, cancer, and autoimmune diseases by achieving balanced immune responses, reducing allergenic reactions, and inducing protective immunity, as demonstrated by the prevention of diabetes incidence and increased IL-10 production in mice models.
Implementation Method 1
the scaffold matrix encapsulates therein, at least, a pro-inflammatory agent, an anti-inflammatory agent
Implementation Method 2
The chemoattractant can be selected from, for example, granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte-colony stimulating factor (G-CSF)
Implementation Method 3
the outer surface of the microparticle comprises one or more surface ligands that bind to a target immune cell
Data Source
AI summary
The present invention provides materials and methods for modulating an immune response. In one embodiment, the present invention provides an initial artificial lymph-node homing environment, and a simultaneous, or subsequent, artificial spleen environment leading to the resolution of the activated immune responses. In one specific embodiment, the present invention can be used to prevent and/or treat pathogenic infection, cancer, allergenic reactions, and/or unwanted immune or auto-immune responses.